This year, in the face of various uncertainties, China’s economy has made its strongest voice – solidly do a good job of “six stable” work, the implementation of the “six” tasks, and strive to complete the year In the face of various uncertainties, China’s economy has made its strongest voice – to do a solid job of “six stable” work, implement the “six protection” tasks, and strive to complete the annual economic and social development goals and tasks. Under the current situation, how can multinational medical and health enterprises achieve growth and development? How to do a good job of stabilizing enterprises and jobs? Johnson & Johnson’s global senior vice president and chairman of China, Song Weiqun, said in an interview with Xinhua recently that Johnson & Johnson insists on the principle of “resuming work and preventing epidemics with both hands, both hands must be hard”, accelerating the introduction of innovative products in the post-epidemic period to ensure the stable production and supply of important medical and health supplies to meet the needs of patients and consumers. At the same time, the company continues to enhance its local innovation and R&D capabilities to make the Chinese market a global innovation engine.
Focus on talent training Prevention and control to resume work both
Employment is an important guarantee for social stability. Since the occurrence of the new crown pneumonia epidemic, the central government has paid great attention to the impact of the epidemic on the employment situation and put forward clear requirements to comprehensively strengthen employment stabilization initiatives. Talking about specific implementation methods, Song Weiqun said that taking care of the employee team has been an important task on the mind of Johnson & Johnson’s management team during this fight against the epidemic. “In order to achieve both prevention and control and return to work, we have not only strictly complied with and implemented the various epidemic prevention measures required by the government, but also introduced humane management measures in offices and factories around the world according to local conditions, such as splitting shifts and increasing the number of workers. such as batch shifts, increased distance between work stations, staggered meals, etc., to achieve scientifically in place prevention and control, orderly resumption of production operations on a safe basis, and increased efficiency.”
Song Weiqun introduced that in addition to caring for the health and safety of employees, Johnson & Johnson put more emphasis on retaining and attracting talent during the epidemic, “We used digital tools to maintain internal communication, deploy strategies and boost morale through online communication conferences, etc., on the one hand, and online training, etc., to help employees improve their business capabilities for returning to work and long-term career development by laying a solid foundation.” He said that in addition to doing a good job of stabilizing the business, some business segments of Johnson & Johnson also adjusted part of the bonus system to protect the financial income of employees and motivate the team according to the impact of the epidemic.
It is understood that, with the strong support of the government and the team’s full cooperation, Johnson & Johnson’s business in the Chinese market recovered rapidly after the epidemic. Johnson & Johnson Medical, for example, has already achieved double-digit growth in the second quarter, which fully illustrates the huge potential and resilience of the Chinese market. “In addition, we are also actively building Johnson & Johnson’s employer brand and continue to add new jobs, with 1,000 more hires planned this year compared to last year.” Song Weiqun introduced that since January, the total number of promotions as well as parallel transfers within Johnson & Johnson has risen by 20% compared to the same period last year, providing employees with a good platform for career development, and the integration and confidence of Chinese employees has increased rather than decreased, ranking first in the global market and becoming an important force for stable employment and development.
Rooted in China to build a global digital development engine
Johnson & Johnson, which has been deeply rooted in China for more than 30 years, has witnessed the take-off of China’s economy. Many companies are facing unprecedented pressure due to the impact of the new crown pneumonia epidemic this year. How can Johnson & Johnson, as a multinational healthcare company, take effective measures to actively cope with the pressure and difficulties? In this regard, Song Weiqun introduced that the Newcastle pneumonia epidemic has indeed brought difficulties and challenges to the industry and enterprises. But at the same time, repeated historical experience proves that every major global or regional crisis contains a strategic opportunity. Our most important task is how to set our eyes on the rare market opportunities that come along with the crisis to better serve patients and the public.
“As one of the first multinational companies to enter the Chinese market after the reform and opening up, Johnson & Johnson has witnessed, participated in and benefited from the rapid development of China’s economy and society, and our mission is to meet the growing demand of the people for high-quality medical and health products and services. As we enter a new era, Johnson & Johnson will also continue to be rooted in China and continue to add to China’s high-quality economic development as one of the main participants in the market.” Song Weiqun said.
He explained that the change in patients’ medical habits brought about by the epidemic, including the behavior of some patients delaying their visits or reducing their trips to other cities, has brought a whole new challenge to the healthcare industry. But at the same time, it also brings new opportunities for industry development and transformation, “in response to the new opportunities brought by the epidemic, Johnson & Johnson has given full play to our innovation capabilities, so as to continue to strengthen our market competitiveness. Currently, in addition to our original business model, our pharmaceutical business is actively expanding into models such as e-hospital (Internet hospital) to provide online consultation and dispensing services for patients. Johnson & Johnson Healthcare is also accelerating the construction of digital diagnosis and treatment, digital professional education, and digital surgery, in an effort to build the Chinese market into a global digital development engine.”
Enhancing innovation and high-end manufacturing capabilities Accelerating the landing of innovative products
Since the founding of New China, China’s healthcare and pharmaceutical sectors have undergone sweeping changes, and healthcare companies have thrived. Among them, R&D and continuous innovation are the core drivers for the development of healthcare companies. How does Johnson & Johnson’s innovative power manifest itself? As a multinational healthcare company with a history of over 130 years, how does it improve its innovative R&D capabilities?
Song Weiqun introduced that since entering the Chinese market, Johnson & Johnson has been committed to working with the government, industry and partners to promote the advancement of healthcare in China and bring more innovative products and services to the Chinese people. Innovation has always been Johnson & Johnson’s greatest asset for success in facing the crisis with ease. In 2019, Johnson & Johnson invested $11.4 billion in global innovation and research and development, ranking among the top in the industry. Currently, Johnson & Johnson’s medical devices, pharmaceuticals and consumer products businesses in China have R&D centers or R&D departments with nearly 700 researchers, the only market other than the United States with complete local R&D capabilities, fully demonstrating the high importance Johnson & Johnson attaches to the Chinese market.
Song Weiqun introduced that Johnson & Johnson’s innovation strategy in China includes three aspects: first, accelerating the introduction of leading global products and technologies. In recent years, the State Drug Administration has done a lot to accelerate the approval of drugs and medical products, and Johnson & Johnson also hopes to take advantage of favorable government policies like the Boao Medical Advance Zone in Hainan, so that the Chinese people can enjoy advanced medical products faster and better in line with international standards. Second, to enhance local innovation and high-end manufacturing capabilities, last year, a brand new supply chain base of Xi’an Janssen Pharmaceuticals Phase II with an investment of nearly $400 million and Johnson & Johnson Medical Suzhou supply chain base with an investment of $180 million were put into production and use. Third, as an industry leader, Johnson & Johnson actively supports the government in building an open innovation ecosystem. In 2019, Asia’s first and the world’s largest Johnson & Johnson incubator opened in Shanghai Zhangjiang Science and Technology Park, and in addition, Shanghai also boasts the fourth Johnson & Johnson Innovation Center in the world outside of Boston, Silicon Valley and London, where the company works with local innovative companies, research units and the government to build a comprehensive The company is building a comprehensive innovation ecosystem through partnerships with local innovative companies, research institutions and government.
It is understood that digital strategy is now one of the most important strategies for all of Johnson & Johnson’s major business areas. In the consumer goods sector, online business already accounts for more than 50% of the overall business volume. At the same time, Johnson & Johnson actively cooperates with leading domestic artificial intelligence and digital surgery companies as well as hospitals to jointly promote the implementation of cutting-edge technologies and products in the healthcare field. Last year, Johnson & Johnson signed a marketing and R&D cooperation agreement with Tianzhihang, the market leader in orthopedic robotics in China. Recently, Johnson & Johnson achieved the first sale of Tianzhihang orthopedic surgery robot in China and officially launched the Tianzhihang Robot Assisted Spine Surgery Clinical Technology Application Center in Shanghai Renji Hospital. In addition, the company’s pharmaceutical company, Xi’an Janssen, signed a memorandum of cooperation with the First Affiliated Hospital of Xi’an Jiaotong University to explore a new model of patient-centered Internet hospital. “In the future, we will continue to work with our Chinese healthcare innovation partners to build a ‘healthy China’ and also hope to bring more Chinese innovations to the world.” Song Weiqun said.
Practicing social responsibility Creating greater value for society
While driving high-quality development with innovation, Johnson & Johnson is also actively practicing corporate social responsibility, committing to social welfare and striving to create greater value for society, said Song Weigun.
“The company practices the spirit of our credo with actions that are responsible for the communities in which we live.” Song Weiqun introduced that paying taxes on time, supporting education, protecting the environment, supporting the disadvantaged and public charity are all part of Johnson & Johnson’s uncompromising efforts over the years. During its 35 years of development in China, Johnson & Johnson has done a lot of work in protecting the Terracotta Warriors and pandas, supporting Operation Smile and neonatal resuscitation to help the development of communities and society as a whole. In the future, Johnson & Johnson will also better leverage its industry expertise to focus on investing greater resources in maternal and infant health, eye health, mental health, and much-needed surgery to drive community progress and improve access to healthcare for the poor.
Song Weiqun introduced the recent announcement that Johnson & Johnson will invest $800 million globally by 2030 to create more sustainable consumer products and make its contribution to protecting a healthy and beautiful planet. At the same time, the concept of environmental protection has been integrated into the company’s daily work, and the office building housing Johnson & Johnson’s China headquarters has received a LEED (Leadership in Energy and Environmental Design) Platinum certification certificate from the U.S. Green Building Council.
“These are all very important strategies and important initiatives that Johnson & Johnson has been practicing to ‘be responsible to the society we live and work in and to the world at large.” It is understood that Johnson & Johnson publishes the Human Health and Sustainability Report every year, which shows in detail the achievements of Johnson & Johnson in practicing its environmental, social and governance commitments, and the company has been widely recognized and affirmed by the community in practicing corporate social responsibility.
本網站內容嚴禁未經授權轉載、複製。本網站僅為一般訊息平台，所發內容不代表本站立場，不構成任何投資、購買、要約等建議，不對資料之完整性、精確性等作任何保證。
